

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Actual results may differ materially from those indicated in the forward-looking statements as a result of various factors, including the clinical results for our drug candidates, which may not support further development or marketing approval; Our reliance on third parties to conduct drug development, manufacturing and other services; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; Our ability to achieve commercial success for our drug candidates, if approved; our ability to obtain and maintain protection of intellectual property for our technology and drugs; And actions of regulatory agencies, which may affect the initiation, timing and progress of our future clinical trials and marketing approval. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. This article should be read completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

**CSTONE APPOINTS THREE DISTINGUISHED ONCOLOGY LEADERS
DRS. PAUL A. BUNN, JR., ELIZABETH M. JAFFEE AND
RICHARD S. FINN TO ITS SCIENTIFIC ADVISORY BOARD**

The following announcement is made by CStone Pharmaceuticals (the “**Company**” or “**CStone**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group:

Shanghai, China, March 25, 2019 – CStone is pleased to announce the appointment of three internationally renowned oncologists Paul A. Bunn, Jr., MD, Elizabeth M. Jaffee, MD, and Richard S. Finn, MD, as the company’s Scientific Advisory Board (“**SAB**”) members. With their deep scientific and medical expertise as well as extensive leadership and advisory experiences at top academic institutions, the addition of these three oncology leaders will greatly augment CStone’s Research and Development strategy in Immuno-Oncology and Precision Medicine and optimize the company’s drug portfolio as a whole.

“It is our great privilege to have Drs. Bunn, Jaffee and Finn on our SAB. We are extremely excited about the guidance and contribution they will provide to accelerate the development of innovative medicine for cancer treatment in China and beyond.” commented Dr. Frank Jiang, Chairman, Executive Director, and CEO of CStone. “We are confident that by leveraging our SAB members’ professional insights, we will further strengthen our oncology pipeline and clinical development capabilities to satisfy the unmet medical needs of Chinese cancer patients by developing innovative combination therapies.”

Paul A. Bunn, Jr., MD is among the world’s leading thoracic oncologists, currently serving as Distinguished Professor at the University of Colorado Cancer Center and James Dudley Professor of Lung Cancer Research at the University of Colorado School of Medicine. He was named “2016 David A. Karnofsky Memorial Award and Lecture recipient”, the most prestigious award of the American Society of Clinical Oncology’s (“**ASCO**”). Among his leadership roles, Dr. Bunn is the former President of ASCO, former Chair of the ASCO Foundation Board, former President of the IASLC, former President of the AACI, former Director of the Univ. of Colorado Comprehensive Cancer Center and former Executive Director of the IASLC. Dr. Bunn also served as the Chairman of the Oncology Drug Advisory Committee of the U.S. FDA. Dr. Bunn is the Chair of the Lung Cancer Mutation Consortium.

Elizabeth M. Jaffee, MD is an internationally recognized expert in cancer immunology and pancreatic cancer, and currently serves as the Deputy Director of the Sidney Kimmel Comprehensive Cancer Center, Deputy Director of the Institute of Clinical and Translational Research, and professor of oncology at Johns Hopkins School of Medicine. Dr. Jaffee has held a string of leadership positions, including the current President of the Board of Directors of the American Association for Cancer Research (“**AACR**”) and co-Chair of the former Blue Ribbon Panel for Vice President Joe Biden’s National Cancer Moonshot Initiative. Her research focuses on cancer immune therapies including novel immune checkpoint inhibitors and cancer vaccines to overcome immune tolerance to cancers.

Richard S. Finn, MD is a leading expert in cancer drug development and liver cancer. He has played a pivotal role in the development of the first CDK4/6 inhibitor palbociclib (Ibrance). Dr. Finn is a Professor of Clinical Medicine in the Hematology/Oncology Division at the David Geffen School of Medicine, and the Director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA. He is the former President of the International Liver Cancer Association, current senior editor of Clinical Cancer Research and Breast Cancer Research, and on the editorial boards of Journal of Hepatology, and Liver Cancer. While dedicating his research to developing molecularly targeted agents and identifying predictive markers of response to novel cancer drugs, Dr. Finn has also served as principal and sub-investigator in clinical trials for targeted and immune-therapies against breast and hepatocellular carcinoma.

About CStone

CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicine to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline with a strategic emphasis on immune-oncology combination therapies. Currently, 4 late-stage candidates are at or near pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model, and substantial funding, CStone's vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: www.cstonepharma.com.

By order of the Board
CStone Pharmaceuticals
Dr. Frank Ningjun Jiang
Chairman

Shanghai, 25 March 2019

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and Executive Director, Dr. Wei Li, Mr. Qun Zhao, Mr. Xiaomeng Tong, Mr. Guobin Zhang and Dr. Lian Yong Chen as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.